EnChannel Medical, a Cuangzhou, China-based innovator in cardiac electrophysiology, closed a Series B financing, raising $82.2M (600M RMB).
The round was co-led by Dragonball Capital and existing investor Lilly Asia Ventures (LAV), with continued support from Lapam Capital.
Proceeds from the Series B round will accelerate product development and advance clinical registration trials both in China and internationally. EnChannel had completed its Series A round of $27.8M (195M RMB) in August 2023.
Founded in 2020 by a team of seasoned electrophysiology innovators from both the United Statesand China, and led by Jun Feng, CEO, EnChannel is developing a holistic platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation to deliver safe and personalized treatment for patients with atrial fibrillation.
Headquartered in Guangzhou, with an R&D subsidiary in Irvine, California, EnChannel is positioned to expand globally.
The DePolar® Mapping System and the NanoAblate® PFA System are investigational devices and are limited by federal (or United States) law to investigational use.
FinSMEs
01/05/2025